RenovoRx Secures FDA Orphan Drug Designation for Oxaliplatin in Pancreatic Cancer
Event summary
- RenovoRx received FDA Orphan Drug Designation for oxaliplatin delivered via RenovoCath for pancreatic cancer treatment.
- This is RenovoRx’s third Orphan Drug Designation, expanding its pipeline and regulatory benefits.
- RenovoCath is an FDA-cleared device for targeted drug delivery, currently in commercialization and clinical trials.
- The TIGeR-PaC Phase III clinical trial for intra-arterial gemcitabine is expected to close enrollment in June 2026.
The big picture
RenovoRx’s FDA Orphan Drug Designation for oxaliplatin underscores its strategic focus on targeted drug delivery for pancreatic cancer, a disease with high unmet medical needs. The designation provides significant regulatory and financial benefits, including seven years of market exclusivity and potential cost savings. This move aligns with broader industry trends toward precision oncology and targeted therapies, positioning RenovoRx to capitalize on the growing demand for innovative cancer treatments.
What we're watching
- Pipeline Expansion
- How RenovoRx will leverage the Orphan Drug Designation to advance its multi-agent, targeted drug-delivery oncology pipeline.
- Commercialization Strategy
- Whether RenovoRx can sustain the momentum in commercializing RenovoCath as a standalone device across leading cancer centers.
- Clinical Trial Outcomes
- The pace at which the TIGeR-PaC Phase III clinical trial for intra-arterial gemcitabine will yield final data readout in mid to late 2027.
Related topics